Residency · Residency · Dermatology

Staphylococcal Scalded Skin Syndrome and Toxic Shock Syndrome

Introduction

Staphylococcal scalded skin syndrome (SSSS) and toxic shock syndrome (TSS) are toxin-mediated diseases caused by Staphylococcus aureus. Both conditions represent dermatologic emergencies requiring rapid diagnosis and treatment. Understanding the pathogenesis, clinical presentation, and management -- and distinguishing these from clinical mimics -- is essential for dermatology trainees.

Staphylococcal Scalded Skin Syndrome

Epidemiology

SSSS predominantly affects neonates and children under five years of age. Adult cases are rare and occur in the setting of renal insufficiency, which impairs clearance of the exfoliative toxins, or immunosuppression. Neonatal outbreaks can occur in nurseries from colonized healthcare workers. Mortality is approximately 3% in children but rises dramatically to 40-60% in adults, reflecting the burden of underlying comorbidities.

Pathogenesis

The disease is caused by exfoliative toxins A and B (ETA and ETB) produced by certain strains of S. aureus belonging to phage group II, types 55 and 71. These exfoliative toxins function as serine proteases that specifically cleave desmoglein 1 (Dsg1), the desmosomal cadherin responsible for cell-cell adhesion in the superficial epidermis. This cleavage occurs in the granular layer, producing superficial intraepidermal splitting. While the toxin has been described as a superantigen in some models, its primary mechanism is targeted proteolysis of Dsg1.

A critical concept is that the site of staphylococcal infection is usually remote from the skin findings. Common primary infection sites include the conjunctivae, umbilical stump, and pharynx. The skin manifestations are entirely toxin-mediated, not due to direct skin infection. Neonatal susceptibility relates to immature renal function, which cannot clear the toxin efficiently, combined with a lack of anti-toxin antibodies.

Clinical Features

The clinical course proceeds through recognizable phases. A prodrome of fever, irritability, and skin tenderness gives way to diffuse, tender erythema beginning on the face, neck, and intertriginous areas, often with a sandpaper texture. This progresses to sterile, flaccid bullae and sheet-like desquamation, where the skin wrinkles and peels off with gentle lateral pressure, constituting a positive Nikolsky sign. Over 7 to 10 days, the skin dries and desquamates, with complete healing occurring without scarring because the cleavage plane is above the basal layer. Perioral crusting and radial fissuring are characteristic findings, and mucous membranes are spared -- a key feature that distinguishes SSSS from toxic epidermal necrolysis (TEN).

<image>Clinical photograph of an infant with SSSS showing diffuse erythema with sheet-like superficial desquamation, perioral crusting and radial fissuring, and a positive Nikolsky sign, alongside a histologic image showing the superficial intraepidermal (subcorneal/granular layer) cleavage plane characteristic of exfoliative toxin-mediated splitting</image>

Diagnosis

The diagnosis is clinical in most pediatric cases. Skin biopsy reveals subcorneal or intragranular acantholysis with minimal inflammation, and the cleavage plane is in the upper epidermis, contrasting with the full-thickness necrosis seen in TEN. Frozen section of peeled skin is a particularly useful bedside tool: a subcorneal split with viable keratinocytes rules out TEN, which shows full-thickness epidermal necrosis. Cultures should be obtained from the suspected primary infection site (nose, throat, umbilicus, eyes, or blood) rather than from the bullae, which are sterile. Unlike pemphigus foliaceus, which also targets Dsg1, SSSS does not involve anti-Dsg1 autoantibodies.

Differential Diagnosis

The primary differential includes toxic epidermal necrolysis, which differs by demonstrating full-thickness epidermal necrosis, mucosal involvement, drug association, and higher mortality. Pemphigus foliaceus is chronic and autoantibody-mediated, sharing a similar cleavage plane but with a different mechanism. Bullous impetigo represents the localized form of exfoliative toxin action, involving the same toxin but producing localized effects.

Management

Treatment centers on antistaphylococcal antibiotics, with IV nafcillin, oxacillin, or cefazolin as first-line agents, and vancomycin or clindamycin when MRSA is suspected. Supportive care includes gentle skin handling, non-adherent dressings, temperature regulation, and fluid and electrolyte management. Bland petrolatum-based emollients protect denuded areas. Acetaminophen is appropriate for pain management, though NSAIDs should be avoided in neonates. Systemic corticosteroids must not be used, as they increase susceptibility to infection without addressing the underlying pathogenesis. Healing is typically complete within 10 to 14 days without scarring, owing to the superficial cleavage plane.

Toxic Shock Syndrome

Staphylococcal TSS

Epidemiology

Staphylococcal TSS was initially described in association with superabsorbent tampon use in menstruating women during the 1980s. However, it is now increasingly recognized in non-menstrual settings, including surgical wound infections, burns, postpartum states, nasal packing, and skin abscesses. Non-menstrual TSS now accounts for the majority of cases.

Pathogenesis

The disease is caused by toxic shock syndrome toxin-1 (TSST-1) and staphylococcal enterotoxins (SEB, SEC). These proteins function as superantigens, binding directly to MHC class II molecules on antigen-presenting cells and the V-beta region of T-cell receptors. This bypasses normal antigen processing and activates up to 20% of all T cells, compared to the 0.01% activated in a normal immune response. The resulting massive cytokine release -- including TNF-alpha, IL-1, IL-2, and IFN-gamma -- leads to capillary leak, hypotension, and multiorgan failure. Most individuals develop protective anti-TSST-1 antibodies over their lifetime; TSS develops in those who lack them.

Clinical Features -- CDC Diagnostic Criteria

The CDC diagnostic criteria require all of the following: fever of at least 38.9 degrees Celsius, hypotension with systolic blood pressure at or below 90 mmHg, a diffuse macular sunburn-like rash (erythroderma), desquamation occurring 1 to 2 weeks after onset (particularly of the palms and soles in a full-thickness, sheet-like pattern), and involvement of three or more organ systems. These organ systems include gastrointestinal (vomiting or diarrhea), muscular (myalgias and elevated CK), mucous membranes (conjunctival or pharyngeal hyperemia, strawberry tongue), renal (elevated creatinine), hepatic (elevated transaminases), hematologic (thrombocytopenia), and central nervous system (disorientation without focal neurologic signs).

<image>Timeline diagram of staphylococcal toxic shock syndrome showing the clinical course: initial fever and erythroderma (day 1-3), multiorgan involvement and hypotension (day 2-7), followed by characteristic desquamation of palms and soles (day 7-14), with corresponding laboratory abnormalities at each phase</image>

Diagnosis

The diagnosis is clinical, based on the CDC criteria. Blood cultures are typically negative in menstrual cases because the disease is toxin-mediated rather than bacteremic. The suspected source site (wound, tampon, abscess) should be cultured. Laboratory findings include leukocytosis, thrombocytopenia, elevated creatine kinase, elevated creatinine, elevated liver function tests, and markers of disseminated intravascular coagulation.

Management

Treatment requires aggressive fluid resuscitation, which may necessitate massive volumes due to capillary leak. Source control is essential: remove any foreign body (tampon, nasal packing), drain abscesses, and debride infected wounds. Antibiotic therapy combines a beta-lactam (nafcillin or oxacillin) with clindamycin, which is a critical adjunct because it inhibits toxin production at the ribosomal level. Intravenous immunoglobulin (IVIG) is considered for severe refractory cases, as it provides neutralizing anti-toxin antibodies. Vasopressors are added if hypotension persists despite adequate fluid resuscitation, and ICU monitoring is indicated for multiorgan failure. Mortality is 3-5% for menstrual TSS and up to 20% for non-menstrual TSS.

Streptococcal TSS

Streptococcal TSS is caused by Group A Streptococcus (GAS) producing superantigens (SpeA, SpeC, SpeJ). Several key features distinguish it from staphylococcal TSS. A soft tissue infection is usually present, such as necrotizing fasciitis, cellulitis, or myositis. Blood cultures are frequently positive because the disease is bacteremic. Mortality is significantly higher, ranging from 30 to 70%. Desquamation is less prominent, and the condition often occurs in otherwise healthy adults with skin or soft tissue GAS infection. Treatment consists of penicillin plus clindamycin, aggressive surgical debridement of necrotizing infections, and IVIG.

Key Distinguishing Features: SSSS vs. TEN

Clinical Pearls

SSSS blisters are sterile, and cultures should be obtained from the remote infection site (nose, throat, umbilicus) rather than from the skin. Frozen section of exfoliated skin rapidly distinguishes SSSS from TEN: a superficial split indicates SSSS while full-thickness necrosis indicates TEN, making this a critical bedside diagnostic tool. Mucosal sparing is the most reliable bedside distinction between SSSS and TEN. In TSS, clindamycin is essential as an adjunct to beta-lactams because it suppresses toxin production at the ribosomal level. Desquamation of the palms and soles occurring 1 to 2 weeks after illness onset is characteristic of TSS and supports retrospective diagnosis.

References

1. Handler MZ, Schwartz RA. Staphylococcal scalded skin syndrome: diagnosis and management in children and adults. J Eur Acad Dermatol Venereol. 2014;28(11):1418-1423.
2. Amagai M, Matsuyoshi N, Wang ZH, et al. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med. 2000;6(11):1275-1277.
3. DeVries AS, Lesher L, Schlievert PM, et al. Staphylococcal toxic shock syndrome 2000-2006. Epidemiol Infect. 2011;139(6):941-951.
4. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009;9(5):281-290.

Read this lecture as Markdown